InChI
1S/Pt
SMILES string
[Pt]
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
assay
99.95%
form
tubes
manufacturer/tradename
Goodfellow 364-153-57
resistivity
10.6 μΩ-cm, 20°C
L × wall thickness
25 mm × 0.2 mm
O.D. × I.D.
6 mm × 5.6 mm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
存储类别
13 - Non Combustible Solids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Thorsten Langer et al.
Trends in pharmacological sciences, 34(8), 458-469 (2013-06-19)
Childhood cancer survival rates are now nearly 80% in more developed European countries because of improved therapies and better supportive care. Platinum chemotherapy drugs, such as cisplatin and carboplatin, are the cornerstone of many effective therapeutic protocols for childhood cancer.
Antonio González
Future oncology (London, England), 9(12 Suppl), 29-35 (2013-11-15)
Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Nicoletta Colombo
Future oncology (London, England), 9(12 Suppl), 19-23 (2013-11-15)
Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice
Hai-Bo Wei et al.
Chinese medical journal, 125(16), 2902-2907 (2012-08-31)
Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持